Trial Profile
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Moclobemide (Primary) ; Nicotine
- Indications Smoking withdrawal
- Focus Therapeutic Use
- 08 May 2015 New trial record